ePrints

Treatment of Non-Alcoholic Fatty Liver Disease

Lookup NU author(s): Dr Jess Dyson, Professor Chris Day

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Abstract: Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of chronic liver disease in developed countries. Treatment depends on the stage of disease, and noninvasive methods for risk stratification are urgently needed. Lifestyle modification (aimed at weight loss and increasing physical activity) and management of the features of metabolic syndrome are vital for all patients with NAFLD. Metformin is the first-line therapy for diabetic patients with NAFLD and also reduces the risk of hepatocellular carcinoma. Clinicians should have a low threshold for introducing a statin for the management of dyslipidaemia. Antihypertensive agents that target the renin-angiotensin system should be first-line in NAFLD for the management of hypertension. For patients with progressive disease, liver-directed pharmacotherapy with vitamin E should be considered. Non-alcoholic steatohepatitis cirrhosis is an increasingly common indication for liver transplantation. ©

Publication metadata

Author(s): Dyson JK, Day CP

Publication type: Article

Publication status: Published

Journal: Digestive Diseases

Year: 2014

Volume: 32

Issue: 5

Pages: 597-604

Print publication date: 01/07/2014

Acceptance date: 01/07/2014

ISSN (print): 0257-2753

ISSN (electronic): 1421-9875

Publisher: S. Karger AG

URL: https://doi.org/10.1159/000360511

DOI: 10.1159/000360511

Altmetrics

Share